Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects.
Over the past few years, advances in the investigation of the neurochemical circuits involved in the development and treatment of alcohol dependence have identified peptides and receptors as potential key targets in the treatment of problems related to alcohol consumption. The endogenous opioid system is modified by alcohol intake in areas of the brain related to reward systems, and differential basal levels of opioid gene expression are found in rodents with a high preference for ethanol. This suggests a greater vulnerability to alcohol consumption in relation to differences in genetic background. Further evidence of the involvement of opioid peptides in alcohol dependence is the ability of the opioid antagonist naltrexone to reduce alcohol intake in animal models of dependence and in alcohol-dependent patients. Abundant evidence indicates that the activation of cannabinoid receptors stimulates the release of opioid peptides, therefore the cannabinoid receptor antagonists may presumably alter opioid peptide release, thus facilitating the reduction of ethanol consumption. However, little is known about the effects of ethanol on the endogenous cannabinoid system, the vulnerability of cannabinoid receptors to alcohol intake or their neurochemical implications in reducing consumption of alcohol. In this paper, we review the role of opioid and cannabinoid receptor systems, their vulnerability to alcohol intake and the development of dependence, and the targeting of these systems in the treatment of alcoholism.
Manzanares
Jorge
J
Edificio Materno-Infantil, Planta 6, 613-A, Hospital Universitario 12 de Octubre, Avda. Cordoba s/n, 28041 Madrid, Spain. jmanzanares6@terra.es
Ortiz
Sergio
S
Oliva
José M
JM
Pérez-Rial
Sandra
S
Palomo
Tomás
T
D000428:Alcohol Drinking / Q000188:drug therapy / Q000378:metabolism; D000437:Alcoholism / Q000503:physiopathology* / Q000517:prevention & control / Q000523:psychology; D000818:Animals; D016739:Behavior, Addictive / Q000209:etiology / Q000523:psychology; D063387:Cannabinoid Receptor Antagonists; D000431:Ethanol / Q000494:pharmacology*; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D043882:Receptors, Cannabinoid / Q000187:drug effects* / Q000378:metabolism; D011957:Receptors, Opioid / Q000187:drug effects* / Q000378:metabolism; D000077285:Rimonabant
D063387:Cannabinoid Receptor Antagonists; D009292:Narcotic Antagonists; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D011957:Receptors, Opioid; D000431:Ethanol; D009271:Naltrexone; D000077285:Rimonabant